| PUBLICATIONS (Ranked by impact factor of the journal) | LABORATORY RESEARCH Regulated Proteolysis of Trop2 Drives Epithelial Hyperplasia and Stem Cell Self-Renewal via β-Catenin Signaling Researchers demonstrated that loss of β-catenin or Trop2 loss-of-function cleavage mutants abrogates Trop2-driven self-renewal and hyperplasia in the prostate. These findings suggest that heightened expression of Trop2 is selected for in epithelial cancers to enhance the stem-like properties of self-renewal and proliferation. [Genes Dev] Full Article | Press Release Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells The effect of glutamate deprivation or blockade by metabotropic glutamate receptor 1 antagonists was investigated on prostate cancer cells’ growth, migration, and invasion to establish biologic relevance. [Clin Cancer Res] Abstract Autophagy Is Differentially Induced in Prostate Cancer LNCaP, DU145 and PC-3 Cells via Distinct Splicing Profiles of ATG5 Autophagic responses to chemotherapeutic agents may vary greatly among different prostate cancer cells and have not been well characterized. Scientists showed that valproic acid induced conversion of LC3-I to LC3-II and formation of LC3 puncta, the typical markers of autophagy, in LNCaP and PC-3 cells. [Autophagy] Full Article Tumor Suppressive miR-124 Targets Androgen Receptor and Inhibits Proliferation of Prostate Cancer Cells The authors completed a series of experiments to understand the functional role of microRNA (miR)-124 in prostate cancer (CaP). They detected the expression level of miR-124 in clinical CaP tissues, evaluated the influence of miR-124 on the growth of CaP cells and investigated the mechanism underlying the dysregulation of miR-124. [Oncogene] Abstract 15- Lipoxygenase-1-Mediated Metabolism of Docosahexaenoic Acid Is Required for Syndecan-1 Signaling and Apoptosis in Prostate Cancer Cells Previous studies have shown that n-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) induces apoptosis in human prostate cancer cells by a syndecan-1-dependent mechanism. Here, scientists examined the contribution of lipoxygenase- and cyclooxygenase-mediated DHA metabolism to this effect. [Carcinogenesis] Abstract Livin Expression May Be Regulated by miR-198 in Human Prostate Cancer Cell Lines Metastatic prostate cancer cell line DU145 expresses high level of Livin mRNA yet low level of its protein. Thus, investigators hypothesized that Livin was regulated by some miRNAs in prostate cancer cells. Livin mRNA and protein expression were investigated by reverse-transcriptase polymerase chain reaction and Western blot, respectively. [Eur J Cancer] Abstract Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells Fn14 expression and tumor necrosis factor-like weak inducer of apoptosis (Tweak) actions were studied in two human prostate cancer cell lines, the androgen-independent PC-3 cell line and androgen-sensitive LNCaP cells. Additionally, the expression of Fn14 was analyzed in human biopsies of prostate cancer. [PLoS One] Full Article Inhibitor of Differentiation 1 (Id1) and Id3 Proteins Play Different Roles in TGFβ Effects on Cell Proliferation and Migration in Prostate Cancer Cells Scientists investigated the role of Id1 and Id3 proteins in the growth inhibitory effects of transforming growth factor β (TGFβ) on prostate cancer cells. [Prostate] Abstract Human Cytosolic Sialidase (NEU2)-Low General Tissue Expression but Involvement in PC-3 Prostate Cancer Cell Survival Researchers found that NEU2 expression assessed by quantitative real-time polymerase chain reaction was extremely low or undetectable in many human tissues and cells, with notable exceptions like the placenta and testis. Among a series of human cancer cell lines examined, only prostate cancer PC-3 cells exhibited relatively high expression and NEU2-silencing with a small interfering RNA resulted in decreased cell survival and motility. [Biochem Biophys Res Commun] Abstract CLINICAL RESEARCH Salvage Intensity-Modulated Radiation Therapy for Locally Recurrent Prostate Cancer after Cryotherapy The authors summarized their results of intensity-modulated radiation therapy (IMRT) for prostate adenocarcinoma after cryotherapy failure. Patients underwent IMRT with curative intent for biochemically recurrent prostate cancer after cryotherapy. [Clin Genitourin Cancer] Abstract |
| REVIEWS | Systematic Review and Meta-Analysis of COX-2 Expression and Polymorphisms in Prostate Cancer Gene polymorphisms in cyclooxygenase-2 (COX-2) have been implicated to alter the risk of prostate cancer (PCa) and overexpression of COX-2 may be associated with clinical and prognostic significance in PCa. However, the results of these studies are inconclusive or controversial. To derive a more precise estimation of the relationships, researchers performed an updated meta-analysis. [Mol Bio Rep] Abstract Benign Prostate Hyperplasia and Stem Cells: A New Therapeutic Opportunity It has been proposed that stromal stem cells in the prostate may be caused by the development of benign prostate hyperplasia (BPH). This review focuses on the putative role of stromal stem or stem-like cells in the development of BPH and assesses the potential of targeting the stem cells for the treatment of BPH. [Cell Biol Toxicol] Abstract |
| INDUSTRY NEWS | Prostate Cancer ‘Dream Team’ Includes UCSC Bioinformatics Experts University of California Santa Cruz (UCSC) biomolecular engineer Joshua Stuart is a principal member of a new “Dream Team” of cancer researchers working to develop personalized treatments for advanced prostate cancer. Stand Up To Cancer and the Prostate Cancer Foundation, along with the American Association for Cancer Research, announced a $10 million, three-year grant to fund the new project, which aims to overcome the treatment resistance that can develop in advanced prostate cancer. [The University of California, Santa Cruz] Press Release OPKO Health to Acquire Prost-Data (OURLab), a Profitable CLIA Laboratory with Strong U.S. Presence in Urologic Pathology OPKO Health, Inc. has entered into a definitive agreement to acquire Prost-Data, Inc., doing business as OURLab. OURLab provides OPKO with a commercial platform to support the near-term U.S. commercial launch of its novel panel of kallikrein biomarkers and associated algorithm for the detection of prostate cancer. [OPKO Health, Inc.] Press Release |
|
|
|